United States Liquid Biopsy Market By Product & Services (Assay Kits, Instruments, Services), By Circulating Biomarker (Circulating Tumor Cells, Circulating Tumor DNA (ctDNA), Cell-free DNA (cfDNA), Others), By Technology (Multi-gene Parallel Analysis using NGS v/s Single-gene Analysis using PCR Microarrays), By Application (Cancer v/s Non-Cancer), By End User (Hospitals & Clinics, Reference Labor
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationUnited States Liquid Biopsy Market By Product & Services (Assay Kits, Instruments, Services), By Circulating Biomarker (Circulating Tumor Cells, Circulating Tumor DNA (ctDNA), Cell-free DNA (cfDNA), Others), By Technology (Multi-gene Parallel Analysis using NGS v/s Single-gene Analysis using PCR Microarrays), By Application (Cancer v/s Non-Cancer), By End User (Hospitals & Clinics, Reference Labor
The United States liquid biopsy market is anticipated to grow at an impressive CAGR for the forecast period, 2023-2027. Rising preference for non-invasive treatment procedures and increasing incidence and prevalence of cancer are the primary factors driving the demand for the United States liquid biopsy market in the forecast period.
Increasing Prevalence of Cancer Drives the Market Growth
Rise in tobacco consumption, lifestyle changes and environmental factors, and contamination with infectious agents such as Hepatitis B and C are some of the factors causing cancer in a large number of individuals. According to WHO, cancer is considered one of the leading causes of death of patients at the global level. Liquid biopsy is in high demand among healthcare professionals for cancer treatment as it is highly effective compared to traditional cancer diagnostics techniques. Liquid biopsy offers several advantages such as increased patient comfort, acquired drug resistance, lower cost, therapy monitoring, early prognosis, and detection of tumor heterogeneity over traditional treatment methods.
Rise In Awareness About Non-Invasive Treatment Method Boosts Market Growth
Liquid biopsy has revolutionized cancer treatment as it is a simple and non-invasive treatment and provides a better alternative to invasive surgical biopsies. It helps the healthcare professionals to discover a plethora of information about the tumor through a simple sample. The method is quick and provides real-time information about the current condition.
At present, liquid biopsy treatment includes circulating tumor DNA (ctDNA), circulating tumor cells (CTC), and exosomes for which the samples can be taken through blood, saliva, urine of the patient. The non-invasive nature of liquid biopsy is the main reason for its high demand among healthcare professionals. It requires only 5 milliliters of blood, making the process tolerable, convenient, and quicker for the patients than the invasive methods. One of the significant advantages of liquid biopsy is it can detect treatment resistance or disease progression beforehand than it appears on imaging scans or shows clinical symptoms.
High Demand for Companion Diagnostics Supports The Market Growth
Companion diagnostics include tests or assays, which play a crucial role in providing cancer patients with information to determine the effective and safe use of the biological product or corresponding drug. Healthcare providers can compare the benefits of the drug, which should ideally outweigh the potential side-effect or risks for the patient.
Companion diagnostics can optimize and improve the drug development process by helping in the identification of safer drugs having higher therapeutic efficacy. They minimize the chances of error and make the drugs affordable and the drug production process more cost-effective. The demand for quality treatment and effective drugs boosts the adoption of companion diagnostics by drug manufacturers and research and diagnostic centers. High penetration of companion diagnostics due to growing awareness about the advantages of the process is expected to support the growth of the United States liquid biopsy market throughout the forecast period.
Click here to download the sample
Market Segmentation
The United States liquid biopsy market is divided into product & services, circulating biomarker, technology, application, end user, regional distribution, and company. Based on the product & services, the market is divided into
Based on the technology, the market is divided into
Market Players
Thermo Fischer Scientific, Inc., Guardant Health, Inc., Biocept, Inc., Roche Diagnostics Corporation, Myriad Genetics, Inc., Exact Sciences Corporation, Illumina, Inc., Bio-Rad Laboratories, Inc., Biocept, Inc., NeoGenomics, Inc., Vortex Biosciences, Inc., Exosome Diagnostics, Inc., Agena Bioscience, Inc., MedGenome Inc., Personal Genome Diagnostics, Inc., are among the major market players operating in the United States liquid biopsy market.
| Attribute | Details |
| Base Year | 2021 |
| Historic Data | 2017 – 2020 |
| Estimated Year | 2022 |
| Forecast Period | 2023 – 2027 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027 |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | · Product & Services · Circulating Biomarker · Technology · Application · End User |
| Regional scope | South, West, Mid-West, North-East |
| Key companies profiled | Thermo Fischer Scientific, Inc., Guardant Health, Inc., Biocept, Inc., Roche Diagnostics Corporation, Myriad Genetics, Inc., Exact Sciences Corporation, Illumina, Inc., Bio-Rad Laboratories, Inc., Biocept, Inc., NeoGenomics, Inc., Vortex Biosciences, Inc., Exosome Diagnostics, Inc., Agena Bioscience, Inc., MedGenome Inc., Personal Genome Diagnostics, Inc. |
| Customization scope | 10% free report customization with purchase. Addition or alteration to regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy